ZENYF - ZENYF STOCK NEWS

ZEN Graphene Solutions Ltd. (TSX-V:ZEN, OTC PINK:ZENYF) has announced its first revenue generation from the commercial shipment of ZENGuard antimicrobial coating to Trebor Rx. This successful transition from bench to pilot scale production enables ZEN to coat the equivalent of 30 million masks monthly. The company reports that its industrial plant's engineering is complete, with procurement underway, aiming for an output of 800 million masks per month. CEO Greg Fenton highlighted this milestone as the start of a significant growth trajectory in the healthcare sector.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has received Health Canada approval for its ZENGuard™ disposable face masks, featuring a biocidal coating and rated ASTM Level 3. This milestone confirms the masks' safety regarding shedding, inhalation, skin irritation, and pathogen deactivation.

CEO Greg Fenton emphasized the significance of this approval for the company's future, especially in high-risk environments. The masks aim to protect frontline workers, and ZEN plans to expand production capacity and pursue international growth.

ZEN Graphene Solutions Ltd. will present at the Sidoti Fall Virtual Investor Conference on September 22-23, 2021. CEO Greg Fenton's presentation is scheduled for September 23 at 8:30 AM ET. Investors can attend the presentation live via the provided link.

ZEN focuses on developing next-gen healthcare solutions, including the ZEN Guard coating, which boasts 99% antimicrobial activity against COVID-19. The company also has an exclusive partnership for a rapid pathogen detection technology.

ZEN Graphene Solutions Ltd. (TSXV:ZEN)(OTC PINK:ZENYF) will hold its Annual General Meeting (AGM) on September 27, 2021, at 4:00 PM EST in Guelph, Ontario, implementing COVID-19 safety protocols including mandatory face coverings and proof of vaccination. Shareholders attending the AGM in person must confirm attendance by September 24. Post-AGM, management will present and host a Q&A session, available via webinar. ZEN focuses on healthcare solutions and is commercializing ZENGuard, a patent-pending antimicrobial coating with potential applications against infectious diseases.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has announced the grant of stock options for two employees, totaling 100,000 common shares at an exercise price of $3.69 each. The options will vest incrementally over 12 months. ZEN focuses on commercializing its patent-pending graphene-based coating, ZEN Guard, which boasts 99% antimicrobial activity, including efficacy against COVID-19. The company's Albany Graphite Project provides a competitive edge in the graphene market, with independent research confirming its suitability for graphene production.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) will hold its 2021 Shareholder Meeting on September 27 at 4 PM in Guelph, Ontario. Attendance is limited to 50 shareholders who register in advance, with proof of vaccination required. Key agenda items include reviewing financial statements, appointing auditors, electing directors, and voting on resolutions related to an omnibus long-term incentive plan and a change of business classification from 'Mining Issuer' to 'Industrial, Technology, or Life Sciences Issuer.' The management information circular will be mailed to shareholders shortly.

ZEN Graphene Solutions announced its application to change its classification on the TSX Venture Exchange from a mining issuer to an industrial, technology, and life sciences issuer. This change reflects ZEN's focus on nanotechnology-enabled healthcare solutions, including its patent-pending ZENGuard coating with 99% antimicrobial activity. The classification change requires TSXV approval and shareholder consent at a meeting on September 27, 2021. CEO Greg Fenton emphasized the need for alignment with the company's core value drivers to enhance shareholder value.

ZEN Graphene Solutions Ltd. has announced the addition of Dr. Kenneth Reed to its Advisory Board. A dermatologist with 38 years of experience, Dr. Reed will focus on advancing ZEN's topical therapeutic applications. He has a strong background in clinical research and has co-founded companies focused on fetal cell detection and fibrotic lung disorders. CEO Greg Fenton emphasized the importance of Dr. Reed’s expertise in navigating regulatory markets and enhancing awareness in the pharmaceutical industry. Dr. Reed has been granted 150,000 options at $3.50 with a three-year vesting period.

ZEN Graphene Solutions Ltd. (TSXV:ZEN, OTC PINK:ZENYF) has signed an exclusive agreement with McMaster University to commercialize a rapid detection technology for SARS-CoV-2. The new saliva-based testing method provides results in under 10 minutes and boasts a clinical sensitivity of 82% and specificity of 100%. The technology was validated through clinical samples under the supervision of leading researchers. A license fee of $100,000 will be paid to McMaster, and provisional patents were filed on June 16, 2021. Final approvals from Health Canada and FDA are pending.